學術發表 - OBI Pharma 台灣浩鼎

2024.Apr.08

ADC

Development of a novel site-specific ADC glycan platform with potential for improved in vivo efficacy and stability of the ADC in animal studies

2023.Dec.19

Vaccine

Investigation of the impact of Globo-H expression on the progression of gastric cancer

2023.May.12

Prodrug

Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, and clinical activity of OBI-3424 in patients with advanced or metastatic solid tumors

2023.Apr.04

Others

Globo H-Targeted CAR T Cell Cancer Immunotherapy

2023.Apr.04

ADC

OBI-999, an anti-Globo H antibody drug conjugate, exhibits synergistic anti-tumor effect in combination with pembrolizumab

2023.Mar.24

Vaccine

Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies

2023.Jan.26

ADC

First-in-Human Study of OBI-999, a Globo H-Targeting Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors

2022.Jun.22

Vaccine

The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer

2022.Jun.06

Vaccine

A phase 3, randomized, open-label study of the anti-Globo H vaccine Adagloxad Simolenin/OBI-821 in the adjuvant treatment of high-risk, early-stage, Globo H-positive triple-negative breast cancer

2022.Jun.05

ADC

First-in-Human Study of OBI-999: a Globo H-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors